ScoreWhy is Halozyme Therapeutics, Inc. ?
1
High Management Efficiency with a high ROCE of 59.50%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 23.90
3
Healthy long term growth as Operating profit has grown by an annual rate 41.43%
4
With a growth in Net Sales of 27.52%, the company declared Very Positive results in Dec 25
- The company has declared positive results for the last 6 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 651.56 MM
- INTEREST COVERAGE RATIO(Q) Highest at 5,723.4
- NET SALES(Q) Highest at USD 451.77 MM
5
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Halozyme Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Halozyme Therapeutics, Inc. for you?
High Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Halozyme Therapeutics, Inc.
-3.53%
0.54
44.24%
S&P 500
16.12%
0.77
19.29%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
39.16%
EBIT Growth (5y)
41.43%
EBIT to Interest (avg)
23.90
Debt to EBITDA (avg)
1.57
Net Debt to Equity (avg)
1.57
Sales to Capital Employed (avg)
0.54
Tax Ratio
19.77%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
59.50%
ROE (avg)
203.20%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
155.43
EV to EBIT
11.76
EV to EBITDA
10.61
EV to Capital Employed
4.66
EV to Sales
6.87
PEG Ratio
0.18
Dividend Yield
NA
ROCE (Latest)
39.63%
ROE (Latest)
1371.85%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
Bullish
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend20What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 651.56 MM
INTEREST COVERAGE RATIO(Q)
Highest at 5,723.4
NET SALES(Q)
Highest at USD 451.77 MM
OPERATING PROFIT(Q)
Highest at USD 281.08 MM
PRE-TAX PROFIT(Q)
Highest at USD 251.92 MM
NET PROFIT(Q)
Highest at USD 211.17 MM
-5What is not working for the Company
DEBT-EQUITY RATIO
(HY)
Highest at 4,167.61 %
INTEREST(Q)
Highest at USD 4.91 MM
EPS(Q)
Lowest at USD -1.2
Here's what is working for Halozyme Therapeutics, Inc.
Operating Cash Flow
Highest at USD 651.56 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
At USD 451.77 MM has Grown at 45.4%
over average net sales of the previous four periods of USD 310.71 MMMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Interest Coverage Ratio
Highest at 5,723.4
in the last five periodsMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Net Sales
Highest at USD 451.77 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD 281.08 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD 251.92 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 211.17 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Net Profit
At USD 211.17 MM has Grown at 41.85%
over average net sales of the previous four periods of USD 148.87 MMMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Depreciation
Highest at USD 26.68 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Depreciation
At USD 26.68 MM has Grown at 30.39%
period on period (QoQ)MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales
Depreciation (USD MM)
Here's what is not working for Halozyme Therapeutics, Inc.
Interest
At USD 4.91 MM has Grown at 14.32%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Interest
Highest at USD 4.91 MM
in the last five periods and Increased by 14.32% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
EPS
Lowest at USD -1.2
in the last five periodsMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (USD)
Debt-Equity Ratio
Highest at 4,167.61 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
